Separate findings on long-term safety and tolerability showed KarXT was generally well tolerated through week 52, with low rates of discontinuation, according to the company. Treatment-emergent adverse events occurred in 65% of participants; serious treatment-emergent adverse events were reported in 7.7%.
KarXT Improves Alzheimer’s Psychosis Scores in Phase 3 Study
Bristol Myers Squibb said preliminary Phase 3 results show its KarXT treatment improved scores for hallucinations and delusions, as well as overall disease severity, in patients with Alzheimer’s disease. The company released the findings Wednesday while awaiting the study’s full results.
When reusing this material a link to Money Talk is required.




Comments (0)
No comments yet. Be the first!